To determine the clinical relevance of our observations, interrogation of the expression of CXCR7 in bladder, breast, cervical, kidney, liver, lung, pancreatic, stomach, and uterine cancers revealed significant poor overall survival in patients with tumors exhibiting elevated gene expression levels of CXCR7 (Fig. 5). This evidence concerns the gene ACKR3 and uterine cancer.